// App-Quantinova.ai

697 : Preclinical Investigation of the p53-MDM2 Antagonist Idasanutlin (RG7388) Demonstrates Significant Activity in High Risk Adult Acute Lymphoblastic Leukemia

Researchers

Presenter

  • Hayden L Bell

Principal Investigators

  • Mankaran Singh

  • Helen J Blair

  • Frederik W. van Delft

  • Anthony V. Moorman

  • John Lunec

  • Julie Irving

Medical Centers

  • Wolfson Childhood Cancer Research Centre,Newcastle University,Newcastle upon Tyne,Vereinigtes Königreich

  • Wolfson Childhood Cancer Research Centre,Newcastle University,Newcastle upon Tyne,Vereinigtes Königreich

  • Paul O'Gorman Building, Newcastle University, Newcastle upon Tyne, ENG, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Hematological malignancies

  • Solid malignancies

  • B-cell acute lymphoblastic leukemia

  • T-cell acute lymphoblastic leukemia

Biomarkers

  • N/A

Drug/Treatment

  • ribose

  • RG7388

  • TP53

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved